A 51-year-old man died final month after receiving an experimental gene remedy developed by Sarepta Therapeutics for an ultra-rare type of muscular dystrophy, an organization spokesperson confirmed Thursday.
He’s the third affected person to die after getting a Sarepta gene remedy this 12 months, all tied to liver points.
Two teenage boys died after receiving Elevidys, Sarepta’s gene remedy for Duchenne muscular dystrophy, forcing the corporate to take the drug off the marketplace for older sufferers. The 51-year-old man was in a scientific trial for limb girdle muscular dystrophy, a group of rarer and usually slower-moving circumstances.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
